Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website

Original Article

Volume 10, Number 11, November 2018, pages 838-842

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes


Figure 1.
Figure 1. Study protocol. Japanese patients with type 2 diabetes were enrolled and followed-up for 24 weeks after switching from glimepiride to repaglinide. Clinical metabolic parameters were measured and recorded at weeks 0 (baseline) and 24.
Figure 2.
Figure 2. Flow chart of patient enrollment throughout the trial.
Figure 3.
Figure 3. Measurement of oxidative stress markers in urine samples collected during treatment with either glimepiride or repaglinide. (a) Glycated hemoglobin (HbA1c); (b) 1,5-anhydroglucitol (1,5-AG); (c) body weight; (d) correlation between the baseline 1.5-AG and Δ1.5-AG are indicated (n = 10). *P < 0.05.


Table 1. Baseline Characteristics of Patients Enrolled in the Study
Data are expressed as mean ± standard deviation. BMI: body mass index; HbA1c: glycated hemoglobin; CPR: C-peptide immunoreactivity; 1,5-AG: 1,5-anhydroglucitol; eGFR: estimated glomerular filtration rate.
Age (years)68.3 ± 8.10
Sex (male/female)7/3
Body weight (kg)59.5 ± 12.3
BMI (kg/m2)23.9 ± 5.12
Duration of diabetes (years)5.5 (4 - 7.8)
HbA1c (%)7.7 ± 0.52
Random plasma glucose (mg/dL)152 ± 51
Random serum CPR (ng/mL)2.6 (1.6 - 3.0)
Baseline 1,5-AG (µg/mL)5.5 ± 2.0
eGFR (mL/min/1.73 m2)73 ± 10
Dyslipidemia (n)4
Hypertension (n)3
Anti-hyperglycemic drugs
Metformin (n)8
Alpha-glucosidase inhibitor (n)1
Pioglitazone (n)5
Dipeptidyl peptidase-4 inhibitor (n)4